Regulatory Compliance

Maple Grove, Minn. – September 30, 2026 -- Upsher-Smith Laboratories, LLC has launched Fluvoxamine Maleate Extended-Release Capsules in 100 mg and 150 mg strengths, entering a U.S. market valued at approximately $44.6 million according to IQVIA data covering August 2025 through July 2026.

Upsher-Smith secures AB-rated status against branded Luvox CR

The product carries a Therapeutic Equivalence (TE) code of AB, with Luvox CR designated as the Reference Listed Drug. The AB rating allows the generic to be considered therapeutically equivalent and substitutable for the brand-name extended-release formulation in U.S. pharmacy channels.

Panama City – September 30, 2026 -- Mercan Group has broken ground on Albor at Santa María, a 48-story, 200-unit residential tower marking its first housing development in Panama and pushing the Canada-headquartered developer's country portfolio past US$200 million.

Panama tightens Qualified Investor real estate thresholds

The groundbreaking follows Executive Decree No. 17, issued September 8, 2026, which keeps the minimum investment for new, first-sale real estate at US$300,000 while setting a US$500,000 threshold for secondary-market properties under Panama's Qualified Investor Program. The decree also adds new investment alternatives and streamlines application procedures.

Chennai – – September 30, 2026 -- MPS Limited said its Artificial Intelligence Management System has been certified to ISO/IEC 42001:2023, the first international standard for AI management systems, following a multi-stage external audit by DNV Business Assurance.

DNV audit confirms governed AI framework across risk, data and oversight controls

The certification, accredited by the Dutch Accreditation Council (RvA), confirms that MPS develops, deploys, and manages AI under a framework covering risk assessment, human oversight, data governance, transparency, and accountability across the full AI lifecycle. Every AI initiative within the certified scope is subject to structured risk and impact assessment, defined controls, and continuous monitoring.

United States – September 30, 2026 -- Column, a nationally chartered bank processing more than $4.5 trillion in annual transaction volume, has partnered with short-term rental platform Guesty to launch purpose-built banking for property managers handling owner and guest funds.

Column brings fiduciary-grade banking to Guesty's 500,000-plus properties

The partnership targets eligible Guesty customers in the United States and internationally, giving operators access to Column deposit and trust accounts designed for fiduciary workflows. Features include separated trust and operating funds, role-based permissions and approval controls, and pass-through FDIC insurance for owner funds, subject to applicable requirements and limits.

Mutual customers also gain direct access to Column's APIs for programmatic banking, backed by a dedicated property management banking team from Column.

New York – September 30, 2026 -- The Women's Sports Foundation (WSF) has released its inaugural WSF Sport Report 2026, a new annual benchmark tracking girls' and women's sports participation from youth leagues through professional and Olympic competition.

Girls pay 25% more than boys to participate in organized sports

Median annual sports spending is $500 for girls compared with $400 for boys, according to the report. Cost is an even greater barrier for girls from lower-income households, who are more than twice as likely as their peers to cite expense as the reason they have never played.

54% of girls who have never played say they want to, nearly matching boys at 52%

Despite similar interest levels, actual participation diverges: 45% of girls ages 8-18 currently play organized sports versus 52% of boys, based on a YouGov survey of more than 6,100 U.S. parents and 3,065 children conducted May 28-June 15, 2026.

New York – September 30, 2026 -- ProphetX, described as America's first federally regulated sports-native prediction market, has signed a technology partnership with Plaee to give distribution operators a single integration point into its CFTC-regulated exchange, avoiding custom builds for each new partner.

Plaee's stack bundles trading, CRM and compliance access for operators

Through the deal, operators connect to ProphetX via Plaee's Prediction Trader, a white-label trading interface, and PlaeeOS, a CRM, personalization and monetization engine. Plaee says the setup lets operators add prediction markets to an existing product line or launch a standalone distribution channel within weeks using their current teams, rather than building exchange connectivity, liquidity access and regulatory infrastructure themselves.

Secaucus, N.J. – September 30, 2026 -- Pierre Fabre Pharmaceuticals Inc. (PFP) has resubmitted a Biologics License Application to the U.S. Food and Drug Administration for tabelecleucel, seeking approval as a monotherapy for adult and pediatric patients aged 2 and older with relapsed or refractory Epstein-Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed at least one prior therapy.

Resubmission follows April 2026 FDA alignment meeting

PFP filed the updated application after reaching agreement with the FDA during an April 2026 Type A meeting. The package includes an expanded dataset with additional patients and longer follow-up from the pivotal Phase 3 ALLELE study, which evaluates tabelecleucel in patients with EBV+ PTLD following hematopoietic cell transplant (HCT) or solid organ transplant (SOT).

Frisco, Texas – September 30, 2026 -- Thirty-one percent of healthcare organizations experienced unauthorized identities accessing sensitive data in the past year, compared with 24% across other industries, according to new healthcare findings from Netwrix's 2026 Data and Identity Security Report. Among healthcare organizations that suffered an incident, 33% reported costs exceeding $250,000, versus 21% in other sectors.

Healthcare ranks last among 16 industries on Active Directory confidence

Only 14% of healthcare organizations said they are fully confident their Active Directory environments are free of privilege escalation risks, compared with 26% across all industries surveyed. Eighty-six percent lack full confidence in their AD security, the lowest ranking among the 16 industries with sufficient survey representation for comparison.

Indianapolis – September 30, 2026 -- Eli Lilly and Company (NYSE: LLY) said its EBGLYSS (lebrikizumab-lbkz) monotherapy met the primary and secondary endpoints of the Phase 3b ADtouch study at Week 16, with more than half of treated patients achieving clear or almost clear skin on hands and feet (HF-IGA 0/1), the company disclosed ahead of the European Academy of Dermatology and Venereology Congress in Vienna, running Sept. 30-Oct. 3.

Trial enrolled 221 patients with moderate-to-severe hand and foot atopic dermatitis

The randomized, double-blind, placebo-controlled ADtouch trial (NCT06921759) assigned 221 adults and adolescents 1:1 to EBGLYSS 250 mg or placebo every two weeks over 16 weeks, following an initial loading dose. Participants had an inadequate response to topical therapies and applied moisturizer throughout the study.

San Jose – September 30, 2026 -- AppZen has launched Autonomous Cards, an AI agent layer that automates compliance, monitoring and spend intelligence for enterprise corporate card programs, as commercial card volume in the U.S. hit $2.23 trillion in 2024, up 4.5% year-over-year, according to the Nilson Report.

AppZen deploys AI agents to process transactions without replacing existing card infrastructure

Autonomous Cards connects directly to companies' existing purchasing, virtual, fleet, ghost, and lodge card programs, keeping current banks and issuers intact while adding a unified AI and compliance layer. The system continuously monitors eligible transactions, using card data, merchant details, Level 3 detail, supporting documents and company policy to determine what was purchased and whether it complies with internal rules.